uploads/2019/04/Graph-2-15-1.png

Bristol-Myers Squibb Reiterates Its 2019 Revenue Guidance

By

Updated

Revenue guidance

In its first-quarter earnings press release, Bristol-Myers Squibb (BMY) reiterated its mid-single-digit YoY (year-over-year) worldwide revenue growth expectation for 2019.

Analysts expect Bristol-Myers Squibb’s revenue to see YoY rises of 6.92% to $24.12 billion in 2019, 4.21% to $25.14 billion in 2020, and 5.14% to $26.43 billion in 2021.

Graph 2

Ready to put your morning scrolling to use? Sign up for Bagels & Stox, our witty take on the top market and investment news straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.

Analysts expect Bristol-Myers Squibb’s revenue to see YoY rises of 6.19% to $6.06 billion in the second quarter, 3.61% to $5.90 billion in the third quarter, and 2.15% to $6.10 billion in the fourth quarter of 2019.

These estimates do not assume a revenue contribution from its Celgene deal, as the transaction has yet to be completed.

To learn more about Bristol-Myers Squibb’s revenue forecasts ahead of its first-quarter earnings results, read Bristol-Myers Squibb’s Revenue Forecast for 2019.

Article continues below advertisement

Growth drivers

In December 2017, Bristol-Myers Squibb issued a press release announcing the FDA’s approval of its drug Opdivo in adjuvant melanoma indications. The European Commission approved Opdivo in adjuvant melanoma indications in July 2018.

Bristol-Myers Squibb is currently advancing several research programs targeting adjuvant melanoma indications. It expects readouts from these trials starting in 2020.

According to the company’s first-quarter earnings conference call, the treatment rates in adjuvant melanoma indications have increased from 20% to 80%. Bristol-Myers Squibb currently accounts for 70% of the US adjuvant melanoma market and is also seeing an encouraging uptake in this indication in certain ex-US markets.

Bristol-Myers Squibb is currently awaiting readouts from multiple trials evaluating its investigational regimens in metastatic settings across a range of oncology indications. Additionally, readouts from the CheckMate 227 and CheckMate 9LA trials, which are expected in 2019 and 2020, respectively, are expected to emerge as key growth drivers for Bristol-Myers Squibb.

Advertisement

More From Market Realist